NeoGenomics Net Income
| NEO Stock | USD 11.38 0.21 1.88% |
As of the 15th of February 2026, NeoGenomics secures the Mean Deviation of 1.82, downside deviation of 2.45, and Risk Adjusted Performance of 0.0602. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeoGenomics, as well as the relationship between them.
NeoGenomics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.4235 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -70.9 M | -67.3 M | |
| Net Loss | -70.9 M | -67.3 M | |
| Net Loss | -129.8 M | -123.3 M | |
| Net Loss | (3.57) | (3.40) | |
| Net Income Per E B T | 1.12 | 1.07 |
NeoGenomics | Net Income | Build AI portfolio with NeoGenomics Stock |
Evaluating NeoGenomics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into NeoGenomics's fundamental strength.
Latest NeoGenomics' Net Income Growth Pattern
Below is the plot of the Net Income of NeoGenomics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in NeoGenomics financial statement analysis. It represents the amount of money remaining after all of NeoGenomics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is NeoGenomics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeoGenomics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (78.73 M) | 10 Years Trend |
|
Net Income |
| Timeline |
NeoGenomics Net Income Regression Statistics
| Arithmetic Mean | (26,507,478) | |
| Coefficient Of Variation | (170.18) | |
| Mean Deviation | 37,243,616 | |
| Median | (1,177,000) | |
| Standard Deviation | 45,111,224 | |
| Sample Variance | 2035T | |
| Range | 152.3M | |
| R-Value | (0.69) | |
| Mean Square Error | 1140.3T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | (6,154,769) | |
| Total Sum of Squares | 32560.4T |
NeoGenomics Net Income History
Other Fundumenentals of NeoGenomics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
NeoGenomics Net Income component correlations
NeoGenomics Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for NeoGenomics is extremely important. It helps to project a fair market value of NeoGenomics Stock properly, considering its historical fundamentals such as Net Income. Since NeoGenomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NeoGenomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NeoGenomics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.
NeoGenomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NeoGenomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NeoGenomics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in NeoGenomics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding NeoGenomics or generate 0.0% return on investment in NeoGenomics over 90 days. NeoGenomics is related to or competes with Exagen, MDxHealth, Stereotaxis, Aclaris Therapeutics, Quanterix Corp, Sagimet Biosciences, and Sanara Medtech. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia More
NeoGenomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NeoGenomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NeoGenomics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.45 | |||
| Information Ratio | 0.0386 | |||
| Maximum Drawdown | 14.15 | |||
| Value At Risk | (4.03) | |||
| Potential Upside | 4.99 |
NeoGenomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeoGenomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NeoGenomics' standard deviation. In reality, there are many statistical measures that can use NeoGenomics historical prices to predict the future NeoGenomics' volatility.| Risk Adjusted Performance | 0.0602 | |||
| Jensen Alpha | 0.1048 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.04 | |||
| Treynor Ratio | 0.1779 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeoGenomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NeoGenomics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0602 | |||
| Market Risk Adjusted Performance | 0.1879 | |||
| Mean Deviation | 1.82 | |||
| Semi Deviation | 2.19 | |||
| Downside Deviation | 2.45 | |||
| Coefficient Of Variation | 1511.59 | |||
| Standard Deviation | 2.54 | |||
| Variance | 6.45 | |||
| Information Ratio | 0.0386 | |||
| Jensen Alpha | 0.1048 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.04 | |||
| Treynor Ratio | 0.1779 | |||
| Maximum Drawdown | 14.15 | |||
| Value At Risk | (4.03) | |||
| Potential Upside | 4.99 | |||
| Downside Variance | 6.02 | |||
| Semi Variance | 4.78 | |||
| Expected Short fall | (1.93) | |||
| Skewness | 0.4763 | |||
| Kurtosis | 1.46 |
NeoGenomics Backtested Returns
NeoGenomics appears to be not too volatile, given 3 months investment horizon. NeoGenomics has Sharpe Ratio of 0.081, which conveys that the firm had a 0.081 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for NeoGenomics, which you can use to evaluate the volatility of the firm. Please exercise NeoGenomics' Downside Deviation of 2.45, risk adjusted performance of 0.0602, and Mean Deviation of 1.82 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, NeoGenomics holds a performance score of 6. The company secures a Beta (Market Risk) of 0.89, which conveys possible diversification benefits within a given portfolio. NeoGenomics returns are very sensitive to returns on the market. As the market goes up or down, NeoGenomics is expected to follow. Please check NeoGenomics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether NeoGenomics' current price movements will revert.
Auto-correlation | -0.19 |
Insignificant reverse predictability
NeoGenomics has insignificant reverse predictability. Overlapping area represents the amount of predictability between NeoGenomics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NeoGenomics price movement. The serial correlation of -0.19 indicates that over 19.0% of current NeoGenomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | -0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.38 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
NeoGenomics Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, NeoGenomics reported net income of (78.73 Million). This is 123.07% lower than that of the Health Care Providers & Services sector and 145.48% lower than that of the Health Care industry. The net income for all United States stocks is 113.79% higher than that of the company.
NeoGenomics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoGenomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics of similar companies.NeoGenomics is currently under evaluation in net income category among its peers.
NeoGenomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NeoGenomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NeoGenomics' managers, analysts, and investors.Environmental | Governance | Social |
NeoGenomics Institutional Holders
Institutional Holdings refers to the ownership stake in NeoGenomics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of NeoGenomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NeoGenomics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 3.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.5 M | Gw&k Investment Management, Llc | 2025-06-30 | 2.5 M | Segall Bryant & Hamill | 2025-06-30 | 2.4 M | Deerfield Management Co | 2025-06-30 | 2.1 M | Hhg Plc | 2025-06-30 | 2 M | Jennison Associates Llc | 2025-06-30 | 1.7 M | Bank Of America Corp | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | Blackrock Inc | 2025-06-30 | 19.4 M | Vanguard Group Inc | 2025-06-30 | 14.1 M |
NeoGenomics Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0303 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 129.39 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 98.06 % | ||||
| Number Of Shares Shorted | 10.02 M | ||||
| Price To Earning | 272.37 X | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 2.08 X | ||||
| Revenue | 660.57 M | ||||
| Gross Profit | 307.81 M | ||||
| EBITDA | (1.51 M) | ||||
| Net Income | (78.73 M) | ||||
| Cash And Equivalents | 465.95 M | ||||
| Cash Per Share | 3.70 X | ||||
| Total Debt | 605.33 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 6.50 X | ||||
| Cash Flow From Operations | 7.02 M | ||||
| Short Ratio | 5.12 X | ||||
| Earnings Per Share | (0.89) X | ||||
| Price To Earnings To Growth | 3.02 X | ||||
| Target Price | 14.43 | ||||
| Number Of Employees | 2.2 K | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 1.47 B | ||||
| Total Asset | 1.64 B | ||||
| Retained Earnings | (325.78 M) | ||||
| Working Capital | 294.78 M | ||||
| Current Asset | 82.36 M | ||||
| Current Liabilities | 40.06 M | ||||
| Net Asset | 1.64 B |
About NeoGenomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoGenomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving together with NeoGenomics Stock
| 0.75 | GH | Guardant Health Earnings Call This Week | PairCorr |
Moving against NeoGenomics Stock
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.